DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA | Zendy

Juan Eduardo MegíasVericat | Zendy; David MartínezCuadrón | Zendy; Joaquín MartínezLópez | Zendy; Juan Bergua | Zendy; Mar Tormo | Zendy; Josefina Serrano | Zendy; Ataulfo González | Zendy; Jaime Pérez de Oteyza | Zendy; Susana Vives | Zendy; MaríaBelén Vidriales | Zendy; Pilar Herrera | Zendy; Juan Antonio Vera | Zendy; Aurelio López Martínez | Zendy; Adolfo de la Fuente | Zendy; María Lourdes Amador | Zendy; JoséÁngel HernándezRivas | Zendy; Ángeles Fernández | Zendy; Carlos Cerveró | Zendy; Daniel Morillo | Zendy; Pilar Hernández Campo | Zendy; Julián Gorrochategui | Zendy; Daniel Primo | Zendy; José Luis Vázquez Rojas | Zendy; Margarita Guenova | Zendy; Joan Ballesteros | Zendy; Miguel Á. Sanz | Zendy; Pau Montesinos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA

Author(s) -

Juan Eduardo MegíasVericat,

David MartínezCuadrón,

Joaquín MartínezLópez,

Juan Bergua,

Mar Tormo,

Josefina Serrano,

Ataulfo González,

Jaime Pérez de Oteyza,

Susana Vives,

MaríaBelén Vidriales,

Pilar Herrera,

Juan Antonio Vera,

Aurelio López Martínez,

Adolfo de la Fuente,

María Lourdes Amador,

JoséÁngel HernándezRivas,

Ángeles Fernández,

Carlos Cerveró,

Daniel Morillo,

Pilar Hernández Campo,

Julián Gorrochategui,

Daniel Primo,

José Luis Vázquez Rojas,

Margarita Guenova,

Joan Ballesteros,

Miguel Á. Sanz,

Pau Montesinos

Publication year - 2019

Publication title -

mediterranean journal of hematology and infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 31

ISSN - 2035-3006

DOI - 10.4084/mjhid.2019.016

Subject(s) - medicine , ex vivo , myeloid leukemia , myeloid , oncology , chemosensitivity assay , cancer research , leukemia , in vivo , chemotherapy , genetics , biology

A third of the patients could benefit from the use of this test in the first line induction therapy selection, although it should be confirmed in a clinical trial specifically designed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research